Abstract
The aim of this study is to in silico screen new glucose-6-phosphate dehydrogenase (G6PD) inhibitors. glucose-6-phosphate dehydrogenase is the first and regulator of pentose phosphate pathway providing NADPH and ribose-5-phosphate required for various syntheses from fatty acids to DNA. G6PD is linked to oxidative stress and hence, to inflammation as well. Therefore, G6PD inhibition is a useful target against inflammation, cancer and some infections. Virtual screening of 15 ligands in the NADP-binding site in comparison with the standard inhibitor 6-aminonicotinamide using iGEMDOCK. Besides, ADME properties of the selected compounds were performed via SWISSADME webserver. All the tested ligands were better than reference inhibitor in terms of binding energy as well as pharmacokinetic and ADME parameters. Moreover, of all tested compounds, ligand 15 showed best docking fitness (-115 Kcal/mole total energy). Novel compounds were screened to be lead inhibitors of G6PD enzyme and ligand 15 ranked first.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
